{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:10:25Z","timestamp":1790259025441,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,6]]},"abstract":"\n Aims<\/jats:title>\n \n To examine the effect of valsartan on kidney outcomes in patients with impaired glucose tolerance (\n IGT<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In a double\u2010blind randomized trial, 9306 patients with\n IGT<\/jats:styled-content>\n were assigned to valsartan (160\u2009mg daily) or placebo. The co\u2010primary endpoints were the development of diabetes and two composite cardiovascular outcomes. Prespecified renal endpoints included: the composite of renal death, end\u2010stage renal disease (\n ESRD<\/jats:styled-content>\n ) or doubling of serum creatinine; estimated glomerular filtration rate (\n eGFR<\/jats:styled-content>\n ) \u226430\u2009\n mL<\/jats:styled-content>\n \/min\/1.73\u2009m\n 2<\/jats:sup>\n ; hospitalization for renal failure; and progression from normoalbuminuria to microalbuminuria, microalbuminuria to macroalbuminuria, and normoalbuminuria to macroalbuminuria. The median follow\u2010up was 6.2\u2009years.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Valsartan reduced the incidence of diabetes but not cardiovascular events. In the valsartan group, 25\/4631 patients (0.5%), vs 26\/4675 (0.6%) patients in the placebo group, developed\n ESRD<\/jats:styled-content>\n or experienced doubling of serum creatinine (hazard ratio [\n HR<\/jats:styled-content>\n ] 0.96, 95% confidence interval [\n CI<\/jats:styled-content>\n ] 0.55\u20101.66;\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009=\u2009.87). Few patients in either group developed an\n eGFR<\/jats:styled-content>\n of \u226430\u2009\n mL<\/jats:styled-content>\n \/min\/1.73\u2009m\n 2<\/jats:sup>\n or had a renal hospitalization. Fewer patients on valsartan (237\/4084 [5.8%]) than on placebo (342\/4092 [8.4%]) developed microalbuminuria (\n HR<\/jats:styled-content>\n 0.68, 95%\n CI<\/jats:styled-content>\n 0.57\u20100.80;\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009<\u2009.0001), and fewer valsartan\u2010treated patients developed macroalbuminuria. Overall, urinary albumin\u2010to\u2010creatinine ratio (\n UACR<\/jats:styled-content>\n ) was 11% lower with valsartan (95%\n CI<\/jats:styled-content>\n 8\u201013;\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009<\u2009.0001) and 9% lower (95%\n CI<\/jats:styled-content>\n 6\u201011;\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009<\u2009.0001) after adjusting for both glucose and blood pressure.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The effect of valsartan on\n UACR<\/jats:styled-content>\n was not wholly explained by change in blood pressure or glucose. Valsartan reduced the incidence of microalbuminuria in\n IGT<\/jats:styled-content>\n without increasing the incidence of hyperkalaemia or renal dysfunction compared with placebo.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12877","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T04:56:27Z","timestamp":1484628987000},"page":"791-799","source":"Crossref","is-referenced-by-count":8,"title":["Effect of valsartan on kidney outcomes in people with impaired glucose tolerance"],"prefix":"10.1111","volume":"19","author":[{"given":"Gemma","family":"Currie","sequence":"first","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Angelyn","family":"Bethel","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Holzhauer","sequence":"additional","affiliation":[{"name":"Novartis Pharma Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Haffner","sequence":"additional","affiliation":[{"name":"Shavano Park San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology, and Metabolism University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,17]]},"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:51:41Z","timestamp":1761886301000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/dom.12877"],"URL":"https:\/\/doi.org\/10.1111\/dom.12877","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}